New drug combo shows promise for colorectal cancer maintenance
NCT ID NCT05775900
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 27 times
Summary
This early-phase study tested a combination of two drugs, cetuximab and capecitabine, given every three weeks as a maintenance treatment for people with a specific type of metastatic colorectal cancer (KRAS/BRAF wild-type). The main goals were to find a safe dose and understand how the body processes the drugs. 24 participants were enrolled, and the study focused on safety and drug levels in the blood.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Sixth Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, 510655, China
Conditions
Explore the condition pages connected to this study.